000028 国药一致
2025/12 -
人民幣(K¥)

变动
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入73,415,858-1.29%75,477,48573,443,13768,357,81059,649,455
减:营业总成本71,812,830-1.65%73,277,09771,309,68866,519,74757,817,567
    其中:营业成本65,575,391-0.84%66,425,42664,516,92660,339,29852,591,767
               财务费用182,960-23.58%204,535189,514212,483119,855
               资产减值损失(290,177)-70.82%(17,577)(71,588)(242,905)(5,179)
公允价值变动收益3,129-115.13%(15,161)28,871----
投资收益217,607-10.00%237,029139,131292,381283,952
    其中:对联营企业和合营企业的投资收益315,684-14.61%315,446298,527333,397354,346
营业利润1,512,829163.80%2,467,4252,306,0691,952,4112,163,841
利润总额1,509,020162.22%2,473,2272,311,0701,974,8532,157,236
减:所得税费用380,67212.47%514,739539,332447,211435,940
净利润1,128,349376.09%1,958,4871,771,7381,527,6421,721,296
减:非控股权益(7,578)-98.13%359,231285,030191,214319,404
股东净利润1,135,92776.80%1,599,2561,486,7081,336,4281,401,893

市场价值指针
每股收益 (元) *2.04077.39%2.8702.6703.1203.270
每股派息 (元) *0.61668.31%0.6800.8000.6000.800
每股净资产 (元) *33.4375.32%31.29037.66634.86132.580
审计意见 #标准无保留意见标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容